South Dakota is currently home to 343 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Sioux Falls, Rapid City, Watertown and Aberdeen. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
NCT05210283
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota
Conditions: Colorectal Cancer
Register for Updates
myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports
NCT05693831
Recruiting
The purpose of this study is to determine the benefit of Cellworks Singula™ reports on physician and molecular tumor board treatment recommendations across a large set of pan-cancer indications who have already received first-line therapy. The study is also to determine the benefit of Cellworks Ventura™ reports on physician and molecular tumor board treatment recommendations across a large set of relapsed or refractory pan-cancer indications. The primary objective of this study is to survey phy... Read More
Gender:
All
Ages:
All
Trial Updated:
01/20/2023
Locations: Avera Cancer Institute, Sioux Falls, South Dakota
Conditions: Cancer, Relapsed Cancer, Refractory Cancer
Register for Updates
Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors
NCT04900519
Recruiting
This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2023
Locations: Sanford Health, Sioux Falls, South Dakota
Conditions: Solid Tumor, Relapsed Solid Neoplasm, Refractory Tumor
Register for Updates
Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen for patIents With Favorable Risk breaSt cancEr
NCT05591547
Recruiting
This study will use an adjuvant radiation therapy regimen called APBI (accelerated partial breast irradiation). APBI is a treatment option available to women considered to have an early stage, low-risk breast cancer. The standard external beam-based APBI treatment delivers treatments every other day for five treatments, over ten calendar days. The APBI in this study is modified and will deliver five once daily treatments over consecutive treatment days, with a slightly lower dose of radiation ea... Read More
Gender:
Female
Ages:
50 years and above
Trial Updated:
11/11/2022
Locations: Sanford Health, Sioux Falls, South Dakota
Conditions: Breast Cancer
Register for Updates
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647
Recruiting
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota
Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.
NCT02075775
Recruiting
This project will be a multi-center, prospective longitudinal cohort for all patients undergoing primary shoulder instability surgery, excluding isolated SLAP repairs. We will be looking for risk factors for recurrent instability, revision surgery, and poor outcomes. Patients will be asked to complete the RAND-36, ASES, Shoulder Activity, EQ-5D and WOSI outcome measures, as well as demographic and socioeconomic information. Surgeons will complete a form after surgery with information on radiogra... Read More
Gender:
All
Ages:
Between 12 years and 99 years
Trial Updated:
11/07/2022
Locations: Orthopedic Institute, Sioux Falls, South Dakota
Conditions: Other Instability, Shoulder, Dislocations, Subluxations, Recurrent Dislocation of Shoulder Region
Register for Updates
A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
NCT04873232
Recruiting
To evaluate the durability of efficacy and long-term safety of intramuscular (IM) administration of Engensis or Placebo that was administered in the double-blind, randomized, VMDN-003-2 Placebo-controlled Phase 3 Study.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/03/2022
Locations: Health Concepts, Rapid City, South Dakota
Conditions: Diabetic Peripheral Neuropathy
Register for Updates
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
NCT04398745
Recruiting
Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at risk or already has renal dysfunction at initial diagnosis. The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in participants with RRMM, who have had at least 3 lin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/01/2022
Locations: GSK Investigational Site, Sioux Falls, South Dakota
Conditions: Multiple Myeloma
Register for Updates
Connect® Myeloid Disease Registry
NCT01688011
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/25/2022
Locations: Prairie Lakes Health Systen, Inc, Watertown, South Dakota
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Register for Updates
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
NCT03926624
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2022
Locations: Avera Medical Group, Sioux Falls, South Dakota
Conditions: Leukemia, Myeloid, Acute
Register for Updates
An Observational, Qualitative Study Assessing Eye Drop Administration
NCT05307081
Recruiting
This is a prospective, observational, consecutive, qualitative, multicenter study. Based on the available published evidence that supports patient challenges with eyedrop administration, the purpose of this video-capture study is to evaluate a more real-world population of consenting patients, regardless of age, with or without visual impairment, at routine eyecare visits. To date, no studies have been performed evaluating a real-world population consisting of daily routine eyecare clinic patie... Read More
Gender:
All
Ages:
All
Trial Updated:
09/13/2022
Locations: Vance Thompson Vision, Sioux Falls, South Dakota
Conditions: Ocular Injury
Register for Updates
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
NCT04880187
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Rapid City Medical Center, Rapid City, South Dakota
Conditions: Non Alcoholic Steatohepatitis (NASH)
Register for Updates